Monday, August 2, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

Video Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Mantle Cell, Diffuse Large B-Cell and Hodgkin Lymphoma

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Monday, August 2nd for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Stephen M Ansell, MD, PhD
Professor of Medicine
Chair, Lymphoma Group
Mayo Clinic
Rochester, Minnesota

Craig Moskowitz, MD
Physician in Chief, Oncology Service Line
Sylvester Comprehensive Cancer Center
Professor of Medicine, Miller School of Medicine
University of Miami Health System
Miami, Florida

Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Associate Editor, Blood
Vancouver, British Columbia, Canada

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, Oncopeptides, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seagen Inc, and Takeda Oncology.

Diffuse Large B-Cell Lymphoma (DLBCL)

  • Optimal selection and sequencing of approved therapies for newly diagnosed and relapsed/refractory (R/R) DLBCL
  • Published research findings with polatuzumab vedotin for patients with R/R DLBCL; optimal incorporation into management algorithms
  • Long-term data with axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel for patients with R/R DLBCL
  • Patient identification and appropriate referral for consideration of CAR (chimeric antigen receptor) T-cell therapy for R/R DLBCL
  • Biologic rationale for and appropriate integration of selinexor into the therapeutic sequence for patients with R/R DLBCL
  • Mechanism of action of tafasitamab and biologic rationale for combining it with lenalidomide for DLBCL; patient selection for treatment with this combination

Mantle Cell Lymphoma (MCL)

  • Best-practice management of newly diagnosed MCL; current role, if any, of novel agents such as lenalidomide or Bruton tyrosine kinase (BTK) inhibitors in up-front treatment
  • Practical incorporation of BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) into the treatment of R/R MCL; key factors in choosing a BTK inhibitor
  • Available data with, current clinical role of and ongoing trials assessing venetoclax for patients with MCL
  • Key clinical research findings with and FDA approval of brexucabtagene autoleucel for MCL; optimal integration into treatment algorithms
  • Available activity and safety data with and ongoing evaluation of BTK inhibitors in combination with Bcl-2 inhibitors for MCL

Hodgkin Lymphoma (HL)

  • Evidence-based systemic approaches in the treatment of newly diagnosed and R/R HL
  • Role of brentuximab vedotin (BV) in combination with AVD (doxorubicin/vinblastine/dacarbazine) as first-line therapy for advanced classical HL; long-term follow-up from the Phase III ECHELON-1 trial
  • Available data with and current role of BV for older patients with newly diagnosed HL
  • Potential role of BV alone or in combination with immune checkpoint inhibition as a bridge to transplant for patients experiencing disease progression on up-front treatment
  • Key efficacy and safety findings from the Phase III KEYNOTE-204 trial evaluating pembrolizumab versus BV for patients with R/R classical HL; implications for clinical practice
  • Published efficacy and safety findings, current role and ongoing evaluation of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic approaches for patients with HL

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

Learning Objectives

  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of each in clinical practice.
  • Assess the FDA-approved indication for selinexor of patients with relapsed/refractory (R/R) DLBCL after at least 2 prior therapies, and consider how this agent can be appropriately and safely incorporated into clinical management algorithms.
  • Understand the mechanism of action of tafasitamab, and appreciate available research data documenting the efficacy and safety of this novel anti-CD19 antibody in combination with lenalidomide for patients with R/R DLBCL.
  • Consider patient age, performance status and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Describe the biologic rationale for, available data with and current clinical role of Bruton tyrosine kinase inhibition for patients with R/R MCL, and discern how these agents can be appropriately and safely integrated into routine practice.
  • Analyze the recent FDA approval of brexucabtagene autoleucel for R/R MCL, and develop an understanding of how this novel therapy can be employed in patient care.
  • Consider clinical, biologic and patient-related factors in the selection of first-line therapy for individuals with newly diagnosed classical Hodgkin Lymphoma (HL).
  • Develop a long-term care plan for patients with R/R HL, considering prior exposure to systemic therapy, eligibility for transplant, symptomatology, performance status and personal goals for treatment.
  • Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, MCL and DLBCL, and obtain consent from appropriate patients for study participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, Oncopeptides, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seagen Inc, and Takeda Oncology.